PubMed holds 148 randomized-trial papers on testosterone replacement for men with low testosterone, and FDA changed its labels in February 2025. That is a real record with plain limits, and it applies to a diagnosed condition.
Whitepill finding
On 2 November 2026, PubMed held 148 randomized-trial papers on testosterone replacement in hypogonadism. On 28 February 2025, FDA told makers to add a blood pressure warning, add trial results, and drop boxed-warning cardiovascular language. These counts show depth of record, not benefit.
The short version
They sayTestosterone is approved for anyone who feels low.
FDA says these products are approved solely for use in men who lack or have low testosterone levels, and keeps its limit on age-related use. See the receipt
They sayThe heart-risk warning was just removed, so it is risk-free.
FDA removed boxed-warning heart language but added a blood pressure warning, saying all testosterone products raise blood pressure. See the receipt
They sayLots of trials means it works for you.
A trial count is depth of record. It does not say who was studied or how big any effect was. See the receipt
Testosterone replacement is the medical use of testosterone for men who lack it or have low levels, which FDA says is the only use its approvals cover.[1] MedlinePlus adds that older men should not usually use testosterone unless they have hypogonadism, and that the testosterone product it describes is a controlled substance.[2]
Whether it suits any person is a question for a clinician and a diagnosis. Some public figures describe using it, and what they have said on the record is on the White Pill Index.
PubMed holds 148 papers typed as randomized controlled trials and 79 systematic reviews or meta-analyses for testosterone replacement in men with hypogonadism or low testosterone.[3]
The tag is PubMed's own publication type.[4] It puts this topic in the middle-to-deep part of the evidence ladder, though it says nothing about who was studied or how large any effect was.
ClinicalTrials.gov lists 117 interventional studies matching testosterone replacement and hypogonadism.[5] A registration is a plan on file, and we have not assessed any of them.
On 28 February 2025, FDA announced class-wide labeling changes. It said ambulatory blood pressure studies confirmed an increase in blood pressure with use of all testosterone products, and that it was adding a new warning about increased blood pressure where one was missing.[1]
It also said it was adding the results of the TRAVERSE trial to all labels and removing language from the Boxed Warning about increased risk of adverse cardiovascular outcomes. The page reports that in that trial there was no increase in the risk of adverse cardiovascular outcomes in men using testosterone for hypogonadism.
FDA kept its limitation of use for age-related hypogonadism, which follows a 2015 safety communication urging caution about using these products for low testosterone due to aging. For how published harm data compares across drug eras, see the steroid era and peptide era harm data.
1. Which condition? FDA's approval is for men who lack or have low testosterone, not for age alone. 2. Who diagnosed it, and with what tests? 3. Read the label's risk list, not the testimonial. 4. A trial in men with hypogonadism is not a trial in men who feel tired. Ask who was studied. 5. This is a prescribing question: a clinician decides.
FDA's page makes blood pressure the headline risk for every product in the class.[1] MedlinePlus, on a page for one now-discontinued product, notes reports of serious side effects in people who use testosterone at higher doses, and says older men should not usually use it unless they have hypogonadism.[2]
Those are class-level cautions, not a risk estimate for you. A prescriber weighs them against your tests and history.
Counts are PubMed records matching a published title and abstract query plus a publication-type filter, and ClinicalTrials.gov interventional studies matching the stated terms, both read 2 November 2026. FDA statements are quoted or closely paraphrased from its 28 February 2025 page, which was read in full on 2 November 2026. The MedlinePlus page covers a discontinued product that is no longer updated, so it is used only for the class-level cautions it states.
Queries are broad and will include off-topic papers, and publication-type tags can be loose, so treat the counts as depth of record (our grading rules are on the methodology page, and every comparison lives on the ladder hub). Nothing here measures effect size, study quality, or safety outcomes in any individual, covers any route, product or schedule, or is medical advice.
("testosterone replacement"[tiab] OR "testosterone therapy"[tiab] OR "testosterone treatment"[tiab]) AND (hypogonadism[tiab] OR "low testosterone"[tiab])testosterone replacement AND hypogonadism, interventional studiesPubMed held 148 papers typed as randomized controlled trials and 79 systematic reviews or meta-analyses for testosterone replacement in hypogonadism or low testosterone on 2 November 2026.
On 28 February 2025 it announced class-wide changes: a new blood pressure warning where one was missing, TRAVERSE trial results added, and boxed-warning language on adverse cardiovascular outcomes removed.
FDA says these products are approved solely for use in men who lack or have low testosterone levels, and it retained its limitation of use for age-related hypogonadism.
No. It means the record is deep. Safety, effect size and your own situation are separate questions for a clinician.
Testosterone replacement has a real trial record and a regulator that changed its labels in 2025, and both concern men with a diagnosed deficiency. Use the count to see that the record exists, then ask a clinician about you.